Treatment options for paediatric diabetes (Q37776269)

23 August 2017

1 reference

title

Treatment options for paediatric diabetes (English)

1 reference

23 August 2017

Alberto Verrotti

1

1 reference

23 August 2017

Rosa Maria Chiuri

2

1 reference

23 August 2017

Annalisa Blasetti

3

1 reference

23 August 2017

Angelika Mohn

4

1 reference

23 August 2017

Francesco Chiarelli

5

1 reference

23 August 2017

language of work or name

English

0 references

publication date

1 October 2010

1 reference

Expert Opinion on Pharmacotherapy

23 August 2017

1 reference

23 August 2017

11

1 reference

23 August 2017

15

1 reference

23 August 2017

2483-2495

1 reference

Definition, epidemiology and classification of diabetes in children and adolescents

23 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

The great weight gain experiment, accelerators, and their implications for autoantibodies in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Type 2 diabetes in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Paediatric diabetes: achieving practical, effective insulin therapy in type 1 and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Microvascular and macrovascular complications associated with diabetes in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Effects of prior hypoglycemia and hyperglycemia on cognition in children with type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Persistent differences among centers over 3 years in glycemic control and hypoglycemia in a study of 3,805 children and adolescents with type 1 diabetes from the Hvidøre Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

The role of new technologies in treating children and adolescents with type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Insulin treatment in children and adolescents with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Insulin analogues: an example of applied medical science

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Insulin lispro: a review of its use in the management of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Insulin lispro: a potential role in preventing nocturnal hypoglycaemia in young children with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Clinical pharmacokinetics and pharmacodynamics of insulin aspart

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Insulin glulisine: an evaluation of its pharmacodynamic properties and clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

A comparison of postprandial and preprandial administration of insulin aspart in children and adolescents with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Effect of age of infusion site and type of rapid-acting analog on pharmacodynamic parameters of insulin boluses in youth with type 1 diabetes receiving insulin pump therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Flexibility of rapid-acting insulin analogues in children and adolescents with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Institution of basal-bolus therapy at diagnosis for children with type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Use of insulin glargine in children under age 6 with type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Combined randomised controlled trial experience of malignancies in studies using insulin glargine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Pharmacology of insulin detemir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Reduced hypoglycemic episodes and improved glycemic control in children with type 1 diabetes using insulin glargine and neutral protamine Hagedorn insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Insulin Detemir Is Characterized by a Consistent Pharmacokinetic Profile Across Age-Groups in Children, Adolescents, and Adults With Type 1 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Recent advances in insulin treatment of children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Initiation of insulin glargine in children and adolescents with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Assessment and monitoring of glycemic control in children and adolescents with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Analysis of guidelines for basal-bolus insulin dosing: basal insulin, correction factor, and carbohydrate-to-insulin ratio

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Intensive vs. conventional insulin management initiated at diagnosis in children with diabetes: should payer source influence the choice of therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Indications for insulin pump therapy in different age groups: an analysis of 1,567 children and adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

The use of insulin pump therapy in the pediatric age group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Are analogue insulins better than soluble in continuous subcutaneous insulin infusion? Results of a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Laboratory-based non-clinical comparison of occlusion rates using three rapid-acting insulin analogs in continuous subcutaneous insulin infusion catheters using low flow rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Assessment of glycemic control by continuous glucose monitoring system in 50 children with type 1 diabetes starting on insulin pump therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Basal insulin supplementation in Type 1 diabetic children: a long-term comparative observational study between continuous subcutaneous insulin infusion and glargine insulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Persistence of benefits of continuous subcutaneous insulin infusion in very young children with type 1 diabetes: a follow-up report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Continuous subcutaneous insulin infusion in toddlers starting at diagnosis of type 1 diabetes mellitus. A multicenter analysis of 104 patients from 63 centres in Germany and Austria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Insulin pump therapy in children and adolescents: improvements in key parameters of diabetes management including quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Durability of insulin pump use in pediatric patients with type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Cost-effectiveness of continuous subcutaneous insulin infusion (CSII) in children: illusion or delusion?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Gene therapy for diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Point: steady progress and current challenges in clinical islet transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Islet transplantation as a treatment for diabetes - a work in progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Primary graft function, metabolic control, and graft survival after islet transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Prolonged insulin independence after islet allotransplants in recipients with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Islet/pancreas transplantation: challenges for pediatrics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Long-term beneficial effect of islet transplantation on diabetic macro-/microangiopathy in type 1 diabetic kidney-transplanted patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Current advances and travails in islet transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Approaches for the cure of type 1 diabetes by cellular and gene therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Cellular therapies for type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Study design of the Trial to Reduce IDDM in the Genetically at Risk (TRIGR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

BABYDIET, a feasibility study to prevent the appearance of islet autoantibodies in relatives of patients with Type 1 diabetes by delaying exposure to gluten

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Vitamin D supplementation in early childhood and risk of type 1 diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Modulating the natural history of type 1 diabetes in children at high genetic risk by mucosal insulin immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Immunotherapy for the prevention and treatment of type 1 diabetes: human trials and a look into the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Immunotherapy of type 1 diabetes: where are we and where should we be going?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Therapy with GAD in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

GAD treatment and insulin secretion in recent-onset type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

The role of immunomodulation therapy in autoimmune diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Oral agents in managing diabetes mellitus in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Management and 1 year outcome for UK children with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes: a randomized, single-blind comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Treatment options for type 2 diabetes in adolescents and youth: a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

Redefining the role of thiazolidinediones in the management of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.506479

10.1517/14656566.2010.506479

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference